Certain cancer cells have regained the ability to grow without glutamine only when vitamin B7 remains available to them.
Without that vitamin, the metabolic workaround collapses, exposing a vulnerability that could reshape how some tumors are targeted.
Cells under nutrient stress
Across multiple cancer cell lines grown under glutamine deprivation, growth resumed only when vitamin B7 was still present in the medium.
By following that unexpected dependency into the mitochondria, Alexis A. Jourdain, Ph.D., at the University of Lausanne (UNIL) documented that pyruvate – a small carbon-rich molecule produced from glucose, – could sustain proliferation only if the vitamin remained available.
Removing B7 did not damage the cells outright, but it stripped them of the ability to use pyruvate as a substitute fuel when glutamine was absent.
That narrow requirement reveals that the apparent flexibility of these tumor cells rests on a single biochemical switch, a constraint that the next section examines in detail.
Why tumors crave glutamine
Fast-growing cells burn through glutamine, an amino acid used to build proteins and genetic material quickly.
Many tumors depend on it for energy production and for making the building blocks of more cells.
In some cancers, that need becomes glutamine addiction, a state where cells stop dividing when glutamine disappears.
Yet many tumor cells find detours, and those detours decide whether glutamine-blocking treatments succeed or fail.
Carbon rescue route
When glutamine runs low, cells can pull carbon from pyruvate, a small molecule made when they break down sugar.
Inside mitochondria, pyruvate can refill the cell’s energy cycle and rebuild missing materials that glutamine normally supplies.
A screen of 371 nutrients found pyruvate boosted growth far more than most nitrogen-rich additives.
That rescue still required a mitochondrial enzyme, and vitamin B7 decided whether the enzyme could function.
How biotin enables growth
To use pyruvate as backup fuel, cells rely on pyruvate carboxylase, an enzyme that refills the energy cycle.
For that switch to flip, vitamin B7 – also called biotin – the form listed on many supplement bottles, had to attach to pyruvate carboxylase.
A National Institutes of Health fact sheet notes that biotin helps several enzymes run, including pyruvate carboxylase, every day.
Without biotin, pyruvate carboxylase stayed inactive, and the backup route collapsed even when that carbon fuel was abundant.
When a gene breaks
Another surprise came from FBXW7, a gene that helps cells dispose of excess proteins daily.
An earlier tumor screen found mutations in this gene across many cancers, setting up a link between genetics and metabolism.
When the gene is mutated – which happens frequently in certain cancers – pyruvate carboxylase partially disappears.
Pyruvate can no longer be used efficiently, and cells become dependent on glutamine, the authors explained.
Once FBXW7 damaged that support, pyruvate could no longer serve as plan B, and glutamine dependence returned.
Why therapies fail
Blocking glutamine has looked tempting because some tumors slow down when that amino acid drops. A major review described years of effort to choke off glutamine use in cancer cells.
Those detours matter in the clinic because a tumor that can run on pyruvate may resist glutamine blockers.
Single-pathway attacks leave room for escape, so future drug plans may need more than one metabolic target.
Mutations seen in patients
Patient-associated FBXW7 mutations did more than change gene labels, and they rewired which fuel routes cells could use.
In lab-built copies of specific patient mutations, cells became glutamine addicted even though the rest of the genome stayed unchanged.
By letting growth signals accumulate, the damaged gene reduced production of pyruvate carboxylase at the source.
Such gene-specific dependencies could help doctors match metabolic drugs to tumors that lack a working backup path.
Coordinated drug design
Combining targets could prevent escape by shutting down both glutamine use and the alternative carbon pathway.
Future drugs might inhibit that key enzyme directly or restrict how tumor cells capture biotin from the bloodstream.
“In the longer term, this research opens up new avenues for better understanding the metabolic vulnerabilities of cancers and for designing innovative therapeutic strategies that take into account the great metabolic flexibility of tumor cells, notably by targeting several metabolic pathways simultaneously,” concluded Jourdain.
Any approach will need careful testing, because healthy tissues also use these same pathways to function.
Testing beyond the lab
For now, the evidence comes from cells and tumor-like spheres grown in lab conditions alone. Inside a person, nutrients rise and fall across tissues, and immune cells and hormones change what tumors can access.
Because laboratory media lets researchers dial vitamins and amino acids up or down, real tumors may respond differently. Next, animal studies and patient samples must show which tumors truly rely on the B7-pyruvate route.
Clinical path forward
A single vitamin requirement has now been linked to whether cancer cells can bypass glutamine addiction or get stuck.
That link gives drug designers a clearer map of where to press, but human trials will decide how usable it becomes.
The study is published in Molecular Cell.
—–
Like what you read? Subscribe to our newsletter for engaging articles, exclusive content, and the latest updates.
Check us out on EarthSnap, a free app brought to you by Eric Ralls and Earth.com.
—–
